Lolupiman Sirisak, Siripurkpong Pilaiwan, Yuvaniyama Jirundon
Department of Biochemistry and Center for Excellence in Protein Structure and Function, Faculty of Science, Mahidol University, Bangkok, Thailand.
Department of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumthani, Thailand.
PLoS One. 2014 Feb 20;9(2):e89424. doi: 10.1371/journal.pone.0089424. eCollection 2014.
Plasmodium falciparum plasmepsin-I (PM-I) has been considered a potential drug target for the parasite that causes fatal malaria in human. Determination of PM-I structures for rational design of its inhibitors is hindered by the difficulty in obtaining large quantity of soluble enzyme. Nearly all attempts for its heterologous expression in Escherichia coli result in the production of insoluble proteins in both semi-pro-PM-I and its truncated form, and thus require protein refolding. Moreover, the yields of purified, soluble PM-I from all reported studies are very limited. Exclusion of truncated semi-pro-PM-I expression in E. coli C41(DE3) is herein reported. We also show that the low preparation yield of purified semi-pro-PM-I with autoprocessing ability is mainly a result of structural instability of the refolded enzyme in acidic conditions due to incomplete formation of disulfide linkages. Upon formation of at least one of the two natural disulfide bonds, nearly all of the refolded semi-pro-PM-I could be activated to its mature form. A significantly improved yield of 10 mg of semi-pro-PM-I per liter of culture, which resulted in 6-8 mg of the mature PM-I, was routinely obtained using this strategy.
恶性疟原虫天冬氨酸蛋白酶-I(PM-I)被认为是导致人类致命疟疾的疟原虫的一个潜在药物靶点。由于难以获得大量可溶性酶,阻碍了为合理设计其抑制剂而对PM-I结构的测定。几乎所有在大肠杆菌中进行其异源表达的尝试都导致在半前体PM-I及其截短形式中产生不溶性蛋白质,因此需要蛋白质复性。此外,所有已报道研究中纯化的可溶性PM-I的产量都非常有限。本文报道了在大肠杆菌C41(DE3)中排除截短的半前体PM-I的表达。我们还表明,具有自加工能力的纯化半前体PM-I制备产量低,主要是由于在酸性条件下复性酶的结构不稳定,这是由于二硫键形成不完全所致。在形成两个天然二硫键中的至少一个后,几乎所有复性的半前体PM-I都可以被激活为其成熟形式。使用该策略常规获得了显著提高的产量,每升培养物可产生10 mg半前体PM-I,从而得到6 - 8 mg成熟的PM-I。